Of Good and Evil: Biological Impact of Endogenous Retroviruses and Other Invasive Genetic Elements
From first retroviral detection in Multiple Sclerosis (MSRV) to the human endogenous retrovirus type W family (HERV-W)
HERV-W/MSRV/Syncytin-1 activation and multiple sclerosis triggers : the EBV/MSRV dual virus hypothesis
Novel therapeutic target in multiple sclerosis : brain tissue and cellular specificities in demyelinated lesions designate human endogenous retrovirus-W envelope protein
Human endogenous retrovirus type W Antigenaemia (MSR Envelope) in patients with CIDP.
MSRV envelope protein is a highly potent agonist of human TLR4 : relevance of GNbAC1 in Chronic Inflammatory Demyelinating Diseases treatment
GNbAC1, a humanized IgG4 antibody neutralizing HERV-W Envelope protein
pre-clinical development and Results from Phase I/IIa clinical trials in Healthy volunteers and in MS patient
"Friendly viruses” : antiviral activities of ERVs against the oncogenic Jaagsiekte sheep retrovirus.
HERV-W/MSRV/Syncytin-1 regulation by HIVtat in blood and brain cells is mediated by Toll-like receptor 4 and TNF-alpha : inference for neuroAIDS
Transcriptional activity of different endogenous retrovirus families in a mouse model of autism
HERV-W expression in immature dendritic cells and macrophages from type 2 diabetes mellitus
Human Endogenous Retrovirus type W is strongly upregulated in T1D pancreas and dysregulates insulin production in vitro and in vivo
From sketches of the HERV transcriptome landscape to the clinical evidence of HERV-H specific retroviruses expression in colorectal carcinoma.
Dysregulation of ERV genes in human pituitary adenoma and glioblastoma multiforme : Possible functional role in giant-cell glioblastoma
HERV-W/MRSV envelope transcripts detection in blood of multiple sclerosis patients after Natalizumab treatment or C. Romano
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.